E-ISSN 2231-3206 | ISSN 2320-4672
 

Case Report

Online Publishing Date:
10 / 08 / 2017

 


Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation

Nithu M Kumar1, Priyanka Sreelatha1, Shine Sadasivan2, Ankur Jain2, Anila K N1.


Abstract
Sorafenib is an oral multikinase inhibitor used as a palliative intent for advanced hepatocellular carcinoma (HCC). Dermatologic toxicity is the main adverse effect limiting its use in many patients. However, Grade III dermatologic toxicity is rarely seen with low-dose sorafenib administration. Here, we discuss the case of a 72-year-old male patient who was treated with sorafenib 400 mg for HCC. After 18 days of administration, the patient complained of intense pain with blisters and ulcerations. The drug was discontinued, and topical corticosteroids and analgesics were given for the management. Review of the patientÂ’s medication did not reveal the presence of any other possible drugs capable of producing dermatological toxicity.

Key words: Hepatocellular carcinoma; Sorafenib; Barcelona Clinic Liver Cancer Staging; Transarterial Chemoembolization


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Nithu M Kumar1
Articles by Priyanka Sreelatha1
Articles by Shine Sadasivan2
Articles by Ankur Jain2
Articles by Anila K N1
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. Natl J Physiol Pharm Pharmacol. 2018; 8(1): 144-145. doi:10.5455/njppp.2018.8.0725025072017


Web Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. https://www.njppp.com/?mno=272281 [Access: March 17, 2024]. doi:10.5455/njppp.2018.8.0725025072017


AMA (American Medical Association) Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. Natl J Physiol Pharm Pharmacol. 2018; 8(1): 144-145. doi:10.5455/njppp.2018.8.0725025072017



Vancouver/ICMJE Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. Natl J Physiol Pharm Pharmacol. (2018), [cited March 17, 2024]; 8(1): 144-145. doi:10.5455/njppp.2018.8.0725025072017



Harvard Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N (2018) Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. Natl J Physiol Pharm Pharmacol, 8 (1), 144-145. doi:10.5455/njppp.2018.8.0725025072017



Turabian Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. 2018. Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. National Journal of Physiology, Pharmacy and Pharmacology, 8 (1), 144-145. doi:10.5455/njppp.2018.8.0725025072017



Chicago Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. "Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation." National Journal of Physiology, Pharmacy and Pharmacology 8 (2018), 144-145. doi:10.5455/njppp.2018.8.0725025072017



MLA (The Modern Language Association) Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N. "Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation." National Journal of Physiology, Pharmacy and Pharmacology 8.1 (2018), 144-145. Print. doi:10.5455/njppp.2018.8.0725025072017



APA (American Psychological Association) Style

Nithu M Kumar, Priyanka Sreelatha, Shine Sadasivan, Ankur Jain, Anila K N (2018) Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation. National Journal of Physiology, Pharmacy and Pharmacology, 8 (1), 144-145. doi:10.5455/njppp.2018.8.0725025072017